STOCK TITAN

ACADIA PHARMACEUTICALS (ACAD) SEC Filings

ACAD NASDAQ

Acadia Pharmaceuticals Inc. filings document the regulatory record for a commercial biopharmaceutical company focused on neurological and rare diseases. Recent Form 8-K reports furnish quarterly and annual operating results, product-sales disclosures for NUPLAZID and DAYBUE, corporate presentations and Regulation FD materials, and updates tied to research-and-development leadership.

Proxy and governance filings describe board composition, committee service, director compensation, executive compensation, equity-incentive awards and annual meeting matters. The filings also record board appointments and resignations, non-employee director compensation under equity plans, and other material-event disclosures affecting Acadia’s governance and capital structure.

Rhea-AI Summary

State Street Corporation reported beneficial ownership of 7,650,889 shares of ACAD common stock, or 4.4%, as of September 30, 2026. It reported shared voting power over 7,263,092 shares and shared dispositive power over 7,650,889 shares, with no sole voting or dispositive power.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.79%
Tags
ownership
-
Rhea-AI Summary

Acadia Pharmaceuticals Inc. (ACAD) reported third-quarter 2026 net product sales of $342.3 million, compared with $278.6 million a year earlier. NUPLAZID contributed $202.2 million and DAYBUE products $140.1 million. Nine-month product sales were $918.3 million, versus $787.5 million.

Third-quarter net income was $53.5 million, compared with $71.8 million; nine-month net income was $88.7 million versus $117.4 million. Operating cash flow for the nine months was $146.3 million, compared with $158.6 million. Cash, cash equivalents and investment securities totaled $976.4 million at September 30, 2026; management said these resources and anticipated product sales would fund planned operations through and beyond the next 12 months.

In the Phase 2 RADIANT study of remlifanserin for Alzheimer’s disease psychosis, the primary endpoint was narrowly missed (p=0.0603), while the key secondary endpoint had nominal significance (p=0.0077). Acadia plans to continue its two ongoing Phase 3 studies using the once-daily 60 mg dose and remove the 30 mg arm. The European Commission authorized DAYBU in August 2026, and its first EU commercial sale occurred in October 2026; a $35.0 million milestone payment to Neuren is due following that sale in the fourth quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
quarterly report
-
Rhea-AI Summary

ACADIA Pharmaceuticals reported third-quarter 2026 GAAP revenue of $342 million, up 23% from $279 million a year earlier; compared with 2025 non-GAAP adjusted revenue of $281 million, the increase was 22%. NUPLAZID sales were $202 million, up 14% year over year, and DAYBUE sales were $140 million, up 39%.

Net income was $54 million, compared with $72 million, and diluted earnings were $0.31 per share versus $0.42. Research and development expense was $76 million versus $88 million, while selling, general and administrative expense was $159 million versus $133 million. Cash, cash equivalents and investment securities totaled $976 million at September 30, 2026.

ACADIA raised 2026 DAYBUE sales guidance to $505–$520 million from $480–$510 million and revised total revenue guidance to $1.265–$1.295 billion from $1.24–$1.30 billion. Phase 2 RADIANT results supported continued Phase 3 development of remlifanserin; the company also received FDA Fast Track designation for the candidate in Lewy body dementia psychosis. Two Phase 2 readouts are anticipated in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
current report
Rhea-AI Summary

ACADIA Pharmaceuticals Inc. Executive Vice President and Chief Financial Officer Mark C. Schneyer acquired 6,815 common shares on October 15, 2026, as performance stock units vested, and sold 3,321 shares on October 30, 2026, at $20.88 per share. The mandatory sale covered withholding taxes and tax-related items imposed by the issuer; the footnote says it was intended to comply with Rule 10b5-1(c).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
insider
-
Rhea-AI Summary

Acadia Pharmaceuticals Inc. said Elizabeth H.Z. Thompson, Ph.D., will stop serving as an employee and as Executive Vice President, Head of Research and Development, effective October 23, 2026. She informed the company on April 27, 2026, of her planned retirement for personal reasons. Effective October 23, she will be retained as a consultant and intends to provide limited consulting services through December 31, 2026. Acadia is identifying a replacement; the company noted that Dr. Thompson may decide not to serve as a consultant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
current report
-
Rhea-AI Summary

ACADIA Pharmaceuticals Inc. reported Phase 2 topline results from the RADIANT program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis. At week 6, once-daily 60 mg remlifanserin had a change from baseline of -12.6 on SAPS-H+D versus -10.4 for placebo (standardized effect size 0.26; p=0.0603). On the key secondary measure, CGI-S-ADP, the changes were -1.3 versus -0.9 (standardized effect size 0.37; nominal p=0.0077). The difference between 60 mg and placebo increased through the six-week treatment period on both measures.

Acadia described safety findings across both doses as favorable, with adverse-event rates similar to placebo, no signal of QT prolongation versus placebo, and no deaths in the remlifanserin treatment arms. The company plans to continue enrolling in two ongoing Phase 3 studies while amending the program, including removing the 30 mg dose arm. Remlifanserin is also being studied in Phase 2 for Lewy body dementia psychosis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.76%
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
current report
-
Rhea-AI Summary

ACADIA Pharmaceuticals’ EVP and CFO Mark C. Schneyer exercised stock options covering 20,141 shares of common stock at an exercise price of $17.84 per share on August 5–6, 2026.

He then sold 20,141 shares in market transactions at prices around $29 per share under a Rule 10b5-1 trading plan adopted on May 19, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
insider
-
Rhea-AI Summary

State Street Corporation has filed as a significant institutional holder of ACADIA PHARMACEUTICALS INC common stock. The filing reports that State Street beneficially owns 9,076,212 shares of common stock, representing 5.3% of the class.

State Street reports no sole voting or dispositive power, but shared voting power over 8,679,785 shares and shared dispositive power over 9,076,212 shares. Subsidiaries involved include SSGA Funds Management, Inc. and several State Street Global Advisors entities, indicating the holdings are managed across affiliated investment advisers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
ownership
Rhea-AI Summary

ACAD officer Mark Schneyer reported a proposed sale of 5,849 common shares, with an aggregate market value of $158,800.35 and an approximate sale date of August 5, 2026. He acquired 5,849 shares from ACAD through a stock option exercise, with cash listed as the payment method, on August 5, 2026. May 19, 2025 is reported as the plan-adoption or instruction date if relying on Rule 10b5-1. Piper Sandler & Co Inc is named as broker.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
other

FAQ

How many ACADIA PHARMACEUTICALS (ACAD) SEC filings are available on StockTitan?

StockTitan tracks 66 SEC filings for ACADIA PHARMACEUTICALS (ACAD), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for ACADIA PHARMACEUTICALS (ACAD)?

The most recent SEC filing for ACADIA PHARMACEUTICALS (ACAD) was filed on November 10, 2026.